|
22 Companies |
|
21 Products |
|
21 Products |
|
24 Mechanisms of Action |
|
0 Trials |
|
313 News |
|
| «123456» |
- ||||| Enrollment closed: Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India (clinicaltrials.gov) - Jun 22, 2014
P3, N=180, Active, not recruiting, Sponsor: Novartis
Recruiting --> Active, not recruiting
- |||| Enrollment open: Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents (clinicaltrials.gov) - Jun 19, 2014
P2, N=300, Recruiting, Sponsor: Novartis
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- rifampicin / Generic mfg.
Trial completion: Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation (clinicaltrials.gov) - Jun 18, 2014
P2, N=30, Completed, Sponsor: Universitas Padjadjaran
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Phase classification: Understanding the Immune Response to Meningitis Vaccines (clinicaltrials.gov) - Jun 12, 2014
P3, N=150, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed Phase classification: P2 --> P3
- |||||| Enrollment open: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. (clinicaltrials.gov) - May 29, 2014
P3, N=150, Recruiting, Sponsor: Novartis
Phase classification: P2 --> P3 Not yet recruiting --> Recruiting
- ||| Trial completion date: Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India (clinicaltrials.gov) - May 27, 2014
P3, N=180, Completed, Sponsor: Novartis
Not yet recruiting --> Recruiting Trial completion date: Jul 2014 --> Apr 2014
- | Enrollment closed: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC (clinicaltrials.gov) - May 25, 2014
P3, N=500, Active, not recruiting, Sponsor: Institute of Tropical Medicine, Belgium
Trial completion date: Jul 2014 --> Apr 2014 Recruiting --> Active, not recruiting
- Trial primary completion date: Nervous System Infections Among Patients With Febrile Seizure (clinicaltrials.gov) - May 18, 2014
P=N/A, N=1200, Completed, Sponsor: H
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Mar 2014
- Trial completion date: Nervous System Infections Among Patients With Febrile Seizure (clinicaltrials.gov) - May 18, 2014
P=N/A, N=1200, Completed, Sponsor: H
Trial primary completion date: Dec 2013 --> Mar 2014 Trial completion date: Dec 2013 --> Mar 2014
- Enrollment change: Nervous System Infections Among Patients With Febrile Seizure (clinicaltrials.gov) - May 18, 2014
P=N/A, N=1200, Completed, Sponsor: H
Trial completion date: Dec 2013 --> Mar 2014 N=1000 --> 1200
- Trial completion: Nervous System Infections Among Patients With Febrile Seizure (clinicaltrials.gov) - May 18, 2014
P=N/A, N=1200, Completed, Sponsor: H
N=1000 --> 1200 Recruiting --> Completed
- |||||||||| New P3 trial: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. (clinicaltrials.gov) - May 15, 2014
P3, N=150, Not yet recruiting, Sponsor: Novartis
- || Trial primary completion date: Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (clinicaltrials.gov) - May 15, 2014
P2, N=500, Active, not recruiting, Sponsor: JN-International Medical Corporation
Recruiting --> Completed Trial primary completion date: Oct 2014 --> May 2014
- || Trial completion date: Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (clinicaltrials.gov) - May 15, 2014
P2, N=500, Active, not recruiting, Sponsor: JN-International Medical Corporation
Trial primary completion date: Oct 2014 --> May 2014 Trial completion date: Oct 2014 --> Nov 2014
- ||| Enrollment closed: Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (clinicaltrials.gov) - May 15, 2014
P2, N=500, Active, not recruiting, Sponsor: JN-International Medical Corporation
Trial completion date: Oct 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- |||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Trial primary completion date: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults (clinicaltrials.gov) - May 14, 2014
P3, N=1300, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Apr 2014
- ||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Trial completion date: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults (clinicaltrials.gov) - May 14, 2014
P3, N=1300, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Aug 2014 --> Apr 2014 Trial completion date: Aug 2014 --> Apr 2014
- ||||||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Trial completion: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults (clinicaltrials.gov) - May 14, 2014
P3, N=1300, Completed, Sponsor: GlaxoSmithKline
Trial completion date: Aug 2014 --> Apr 2014 Active, not recruiting --> Completed
- ||||| New P2 trial: Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents (clinicaltrials.gov) - May 14, 2014
P2, N=300, Not yet recruiting, Sponsor: Novartis
- || Trumenba (meningococcal B vaccine) / Pfizer
Trial primary completion date: A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age (clinicaltrials.gov) - May 13, 2014
P2, N=2625, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Jun 2014
- || Trumenba (meningococcal B vaccine) / Pfizer
Trial completion date: A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age (clinicaltrials.gov) - May 13, 2014
P2, N=2625, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Apr 2014 --> Jun 2014 Trial completion date: Apr 2014 --> Jun 2014
- || Trumenba (meningococcal B vaccine) / Pfizer
Trial completion date: A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents (clinicaltrials.gov) - May 13, 2014
P2, N=539, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Apr 2014 --> Jun 2014 Trial completion date: Apr 2014 --> May 2014
- ||||| Trumenba (meningococcal B vaccine) / Pfizer
Enrollment closed: A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years (clinicaltrials.gov) - May 13, 2014
P3, N=5700, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Apr 2014 --> May 2014 Recruiting --> Active, not recruiting
- | Trial primary completion date: A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults (clinicaltrials.gov) - May 12, 2014
P3, N=18, Active, not recruiting, Sponsor: Novartis Vaccines
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2014 --> Mar 2014
- |||| Trial primary completion date: Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine (clinicaltrials.gov) - Apr 14, 2014
P3, N=433, Completed, Sponsor: Novartis Vaccines
Trial primary completion date: Apr 2014 --> Mar 2014 Trial primary completion date: Jul 2013 --> Apr 2013
- ||| Trial completion date: Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine (clinicaltrials.gov) - Apr 14, 2014
P3, N=433, Completed, Sponsor: Novartis Vaccines
Trial primary completion date: Jul 2013 --> Apr 2013 Trial completion date: Jul 2013 --> Apr 2013
- ||||||| Trial completion: Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine (clinicaltrials.gov) - Apr 14, 2014
P3, N=433, Completed, Sponsor: Novartis Vaccines
Trial completion date: Jul 2013 --> Apr 2013 Recruiting --> Completed
- Trial withdrawal: Feasibility Study of Auditory Brainstem Implant in Young Children (clinicaltrials.gov) - Apr 9, 2014
P1, N=10, Withdrawn, Sponsor: House Research Institute
Recruiting --> Completed Not yet recruiting --> Withdrawn
- ||||||| Trial completion: Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. (clinicaltrials.gov) - Apr 7, 2014
P3, N=264, Completed, Sponsor: Novartis
Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- |||||||||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
New P3 trial: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Apr 6, 2014
P3, N=750, Not yet recruiting, Sponsor: Novartis
- | Enrollment change: A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults (clinicaltrials.gov) - Apr 1, 2014
P3, N=18, Active, not recruiting, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed N=130 --> 18
- | Enrollment closed: A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults (clinicaltrials.gov) - Apr 1, 2014
P3, N=18, Active, not recruiting, Sponsor: Novartis Vaccines
N=130 --> 18 Recruiting --> Active, not recruiting
- Clinical data: Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=195, Completed, Sponsor: Mahidol University
- | Trumenba (meningococcal B vaccine) / Pfizer
Enrollment change: B1971042: Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ?18 To ?65 Years Of Age (clinicaltrials.gov) - Mar 16, 2014
P2, N=13, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting N=70 --> 13
- | Trumenba (meningococcal B vaccine) / Pfizer
Trial completion: B1971042: Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ?18 To ?65 Years Of Age (clinicaltrials.gov) - Mar 16, 2014
P2, N=13, Completed, Sponsor: Pfizer
N=70 --> 13 Active, not recruiting --> Completed
- Enrollment open: PreColos: Feeding Bovine Colostrum to Preterm Infants (clinicaltrials.gov) - Mar 13, 2014
P=N/A, N=50, Recruiting, Sponsor: Arne Astrup
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Bexsero (meningococcal group B vaccine) / GSK
New P4 trial, IO biomarker: Investigating the Immune Response to 4CMenB in Infants (clinicaltrials.gov) - Mar 4, 2014
P4, N=160, Not yet recruiting, Sponsor: University of Oxford
- Cubicin (daptomycin) / Merck (MSD)
Trial suspension, Gram positive: Daptomycin in Pediatric Patients With Bacterial Meningitis (clinicaltrials.gov) - Mar 2, 2014
P1, N=5, Suspended, Sponsor: University Hospital Inselspital, Berne
Not yet recruiting --> Recruiting Recruiting --> Suspended
- ||||| Enrollment closed: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years (clinicaltrials.gov) - Feb 25, 2014
P3b, N=1400, Active, not recruiting, Sponsor: Novartis Vaccines
Recruiting --> Suspended Recruiting --> Active, not recruiting
- |||| NN1213 / Novo Nordisk
Trial completion: Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis (clinicaltrials.gov) - Feb 19, 2014
P2, N=60, Completed, Sponsor: InterMune
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- | busulfan / Generic mfg.
Trial completion: Busulfan in Treating Children and Adolescents With Refractory CNS Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=28, Completed, Sponsor: Pediatric Brain Tumor Consortium
No longer recruiting --> Completed No longer recruiting --> Completed
- Enrollment change: Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=75, Completed, Sponsor: University of Michigan
No longer recruiting --> Completed N=100 --> 75
- Trial completion: Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=75, Completed, Sponsor: University of Michigan
N=100 --> 75 Active, not recruiting --> Completed
- || Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Enrollment closed: Safety of MenACWY-CRM Vaccination in Adolescents (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=55429, Active, not recruiting, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial initiation date: Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos (clinicaltrials.gov) - Jan 30, 2014
P1, N=60, Not yet recruiting, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Recruiting --> Active, not recruiting Initiation date: Sep 2013 --> Mar 2014
- ceftriaxone / Generic mfg., gentamicin sulfate / Generic mfg.
Enrollment closed: Infaseme: Infant Severe Sepsis and Bacterial Meningitis in Malawi (clinicaltrials.gov) - Jan 14, 2014
P4, N=238, Active, not recruiting, Sponsor: University of Malawi College of Medicine
Initiation date: Sep 2013 --> Mar 2014 Recruiting --> Active, not recruiting
- ||| Biomarker, Trial completion: CURIOSITY: Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections (clinicaltrials.gov) - Dec 28, 2013
P=N/A, N=1001, Completed, Sponsor: MeMed Diagnostics Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Enrollment change: Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine (clinicaltrials.gov) - Dec 16, 2013
P3, N=389, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed N=866 --> 389
- |||||||||| New P3 trial: Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine (clinicaltrials.gov) - Dec 4, 2013
P3, N=2195, Recruiting, Sponsor: Beijing Minhai Biotechnology Co., Ltd
- |||||||||| New P3 trial: Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine (clinicaltrials.gov) - Dec 4, 2013
P3, N=1260, Recruiting, Sponsor: Beijing Minhai Biotechnology Co., Ltd